<DOC>
	<DOCNO>NCT01798992</DOCNO>
	<brief_summary>The primary goal study measure intact human heart , alteration gene expression time associate reverse remodel response β-blockade . The second goal investigate signal mechanism turn responsible change gene expression , third goal determine relationship intrinsic systolic dysfunction remodel leave ventricle . This accomplish measure ventricular size , function , gene expression myocardial tissue sample obtain percutaneous biopsy prior initiation β-blockade 3 12 month start therapy . The specific Aims Hypotheses test : 1 . Aim : Determine change gene expression associate change intrinsic systolic function functional decompensation intact , fail human heart . a. Hypothesis : Changes expression select gene precede accompany change leave ventricular systolic function human idiopathic dilate cardiomyopathy ( IDC ) . 2 . Aim : Identify signal mechanism responsible alteration expression key gene involve mediation ventricular hypertrophy contractile dysfunction . a. Hypothesis : Myocardial-failure-associated regulation select messenger ribonucleic acid protein related leave ventricular wall stress neurohormonal signaling . 3 . Aim : In relationship contractile dysfunction dilatation/remodeling , determine relationship contractile dysfunction structural remodeling . b. Hypothesis : contractile dysfunction primary structural remodel secondary .</brief_summary>
	<brief_title>Effect Beta-blockers Structural Remodeling Gene Expression Failing Human Heart</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Idiopathic dilate cardiomyopathy New York Heart Association Class IIIV symptoms No evidence coronary artery disease angiography within 2 year randomization If female , patient ( ) surgically sterile ( b ) practice accept method birth control negative serum pregnancy test Patient conventional cardiac heart failure ( CHF ) therapy least 3 week prior baseline assessment ( include angiotensin convert enzyme inhibitor , digoxin , diuretic , and/or vasodilator ) Patient leave ventricular ejection fraction &lt; 40 % radionuclide ventriculography within 60 day randomization Patient must demonstrate mental physical ability willingness follow studyspecific instruction Patient must voluntarily sign Institutional Review Board ( IRB ) approve informed consent form prior studyspecific procedure Patient heart failure due associate uncorrected primary valvular disease , uncorrected thyroid disease , obstructive/hypertrophic cardiomyopathy , pericardial disease , amyloidosis , active myocarditis , malfunction artificial heart valve . Patient actively heart transplant list anticipate within 6 month randomization Patient receive follow medicine : 1 . Calcium channel blocker 2 . Theophylline 3 . Tricyclic antidepressant 4 . Monoamine oxidase inhibitor 5. βagonists 6. βadrenergic block agent ( oral ) 7 . Any investigational cardiovascular medication involvement another investigational trial 8 . Flecainide , encainide , propafenone , sotalol , disopyramide , amiodarone Patient contraindication βblockade ( eg asthma ) Patient another lifethreatening disease life expectancy &lt; 2 year due illness Patient active hepatic , renal , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system disease may adversely affect safety efficacy study drug life span patient Unstable decompensated heart failure ( evidence hypoperfusion , acute pulmonary edema , hypotension SBP &lt; 80 mm Hg ) Patient actively abuse ethanol illicit drug within 3 month randomization Patient automatic implantable cardiac defibrillator fire within 3 month randomization Patient asymptomatic waking , rest heart rate &lt; 50 bpm symptomatic bradycardia &lt; 60 bpm . Patient uncontrolled insulindependent diabetes mellitus history frequent hypoglycemia episode Patient high degree atrioventricular block ( Mobitz Type II complete heart block ) Patient unable tolerate magnetic resonance imaging procedure Patient demonstrate noncompliance previous medical regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ejection fraction</keyword>
	<keyword>beta-blocker</keyword>
	<keyword>carvedilol</keyword>
	<keyword>metoprolol</keyword>
	<keyword>myocardial gene expression</keyword>
	<keyword>human heart</keyword>
	<keyword>ventricular remodel</keyword>
	<keyword>wall stress</keyword>
	<keyword>adrenergic signal</keyword>
	<keyword>myosin heavy chain</keyword>
</DOC>